ConductScience.org, home

Paper11259554

Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.

Hatzelmann A and 1 other. J Pharmacol Exp Ther, 2001. Cited by 323 papers, by iCite.

Cite this record

ConductScience Library. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Papers, record 11259554. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11259554

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro.
PubMed
Journal
J Pharmacol Exp Ther
PubMed
Year
2001
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
323
iCite
Relative citation ratio, by iCite
8.12
iCite
Revised in PubMed
2014-11-20
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Hatzelmann AA
2Schudt CC

Source PubMed

Download CSV of authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
3',5'-Cyclic-AMP PhosphodiesterasesMajor topic
Anti-Inflammatory Agents, Non-SteroidalMajor topic
Immunosuppressive AgentsMajor topic
Phosphodiesterase InhibitorsMajor topic
Aminopyridines
Benzamides
CD4-Positive T-Lymphocytes
Cyclic Nucleotide Phosphodiesterases, Type 1
Cyclic Nucleotide Phosphodiesterases, Type 4
Cyclopropanes
Cytokines
Dendritic Cells
Eosinophils
Humans
In Vitro Techniques
Luminescent Measurements
Lymphocyte Activation
Monocytes
Neutrophils
Pyridazines
Tumor Necrosis Factor-alpha

Source PubMed

Download CSV of topics

Cited by118

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 323 citations.

PMIDTitleJournalYearIn PapersSource
42897680Roflumilast mitigates cartilage degeneration in osteoarthritis by activating CFTR-mediated anti-apoptotic signaling.Arthritis Res Ther2026https://conductscience.org/library/papers/42897680PubMed
42368799Psychiatric events induced by roflumilast: a real-world pharmacovigilance study of the FDA Adverse Event Reporting System database.Front Psychiatry2026https://conductscience.org/library/papers/42368799PubMed
42181088Practical considerations for managing patients being treated with topical roflumilast.J Pharm Pharm Sci2026https://conductscience.org/library/papers/42181088PubMed
41787480A small‑molecule HDAC/PDE modulator activates human adipocyte UCP1 and resolves inflammatory signaling.J Transl Med2026https://conductscience.org/library/papers/41787480PubMed
41594619Trends in Inhibitors, Structural Modifications, and Structure-Function Relationships of Phosphodiesterase 4: A Review.Biomolecules2026https://conductscience.org/library/papers/41594619PubMed
40783516Comparison of cilomilast, tadalafil, and both drug combinations in the treatment of monocrotaline-induced pulmonary arterial hypertension in rats.BMC Cardiovasc Disord2025https://conductscience.org/library/papers/40783516PubMed
40358183Advancing Obstructive Airway Disease Treatment: Dual PDE3/4 Inhibition as a Therapeutic Strategy.Cells2025https://conductscience.org/library/papers/40358183PubMed
40276862Effectiveness and safety of topical phosphodiesterase 4 inhibitors in children with mild-to-moderate atopic dermatitis: A systematic review and meta-analysis.J Int Med Res2025https://conductscience.org/library/papers/40276862PubMed
40192433Distinct Impact of Phosphodiesterade-4 (PDE4) Inhibition in Two Pre-clinical Psoriasis Models.Acta Derm Venereol2025https://conductscience.org/library/papers/40192433PubMed
40081105Cyclic nucleotide phosphodiesterases as drug targets.Pharmacol Rev2025https://conductscience.org/library/papers/40081105PubMed
39942796Molecular Properties of Phosphodiesterase 4 and Its Inhibition by Roflumilast and Cilomilast.Molecules2025https://conductscience.org/library/papers/39942796PubMed
39679247Topical Application of Dipyridamole and Roflumilast Combination Nanoparticles Loaded Nanoemulgel for the Treatment of Psoriasis in Rats.Int J Nanomedicine2024https://conductscience.org/library/papers/39679247PubMed
39223490Phosphodiesterase 4 is overexpressed in keloid epidermal scars and its inhibition reduces keratinocyte fibrotic alterations.Mol Med2024https://conductscience.org/library/papers/39223490PubMed
38807127MnO2 and roflumilast-loaded probiotic membrane vesicles mitigate experimental colitis by synergistically augmenting cAMP in macrophage.J Nanobiotechnology2024https://conductscience.org/library/papers/38807127PubMed
38688656The Effect of Roflumilast on Lipopolysaccharide-induced Acute Lung Injury During Neutropenia Recovery in Mice.In Vivo2024https://conductscience.org/library/papers/38688656PubMed
36813290Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.Eur Respir Rev2023https://conductscience.org/library/papers/36813290PubMed
35942000Longstanding hypersensitivity pneumonitis and its response to roflumilast: A review of its likely immunological effects.Respir Med Case Rep2022https://conductscience.org/library/papers/35942000PubMed
35517783BI 1015550 is a PDE4B Inhibitor and a Clinical Drug Candidate for the Oral Treatment of Idiopathic Pulmonary Fibrosis.Front Pharmacol2022https://conductscience.org/library/papers/35517783PubMed
35163131Clinical Implication of Phosphodiesterase-4-Inhibition.Int J Mol Sci2022https://conductscience.org/library/papers/35163131PubMed
35057082The Compound (E)-2-Cyano-N,3-diphenylacrylamide (JMPR-01): A Potential Drug for Treatment of Inflammatory Diseases.Pharmaceutics2022https://conductscience.org/library/papers/35057082PubMed

See all 118 cited byDownload CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11259554

GET https://conductscience.org/api/papers/v1/11259554/cited_by?page=2